For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 13,606 | 28,563* | 17,441 | 18,022 |
| General and administrative | 5,360 | 8,037* | 5,091 | 5,451 |
| Impairment charge | - | -6,350* | - | 3,175 |
| Total operating expenses | 18,966 | 30,250 | 22,532 | 26,648 |
| Loss from operations | -18,966 | -30,250* | -22,532 | -26,648 |
| Interest income | 1,182 | 1,102* | 802 | 1,106 |
| Interest expense | 331 | 383* | 408 | 405 |
| Other income (expense), net | 188 | -24* | -6 | -2 |
| Loss before income taxes | - | -29,555* | - | - |
| Income tax provision | - | 0* | - | - |
| Net loss | -17,927 | -29,555 | -22,144 | -25,949 |
| Basic EPS | -0.17 | -0.548 | -0.41 | -0.49 |
| Diluted EPS | -0.17 | -0.548 | -0.41 | -0.49 |
| Basic Average Shares | 104,573,657 | 53,952,500 | 53,577,066 | 53,445,631 |
| Diluted Average Shares | 104,573,657 | 53,952,500 | 53,577,066 | 53,445,631 |
ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX ONCOLOGY HOLDINGS INC (ALXO)